Objective To explore the clinical effect of Yangyin Qingfei Granules combined with isoniazid+rifampicin+pyrazinamide+ethambutol(HRZE)chemotherapy in the treatment of newly diagnosed sensitive pulmonary tuberculosis.Methods Clinical data of 95 newly treated sensitive pulmonary tuberculosis patients admitted to Henan Provincial Chest Hospital from June 2022 to March 2023 were retrospectively collected.They were divided into a control group(47 cases,treated with HRZE chemotherapy regimen)and an observation group(48 cases,treated with HRZE chemotherapy regimen and Yangyin Qingfei Granules)according to different treatment plans,all of which were continuously treated for 6 months.The efficacy,lung function indexes(forced vital capacity,peak expiratory flow,forced expiratory volume in the first second),immune function indexes and side effects during treatment were compared in both groups.Results The total effective rate of observation group was higher than that of control group(P＜0.05).At 6 months of treatment,the lung function and immune function indicators in the observation group were higher than those in the control group(P＜0.05).There was no statistical significant difference in the total incidence of adverse reactions between the two groups(P＞0.05).Conclusion The combination of HRZE chemotherapy regimen and Yangyin Qingfei Granules has a significant therapeutic effect on newly treated sensitive pulmonary tuberculosis patients,which can improve their immune and lung functions without increasing the incidence of side effects.
维普
万方数据